Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study involves the administration of a hypoxia marker, pimonidazole hydrochloride, taken orally approximately 24 hours before surgical resection of a pancreatic tumor in order to identify areas of lower oxygen content on tumor samples.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto

Criteria

Inclusion Criteria:

• age > 18

• provisional diagnosis of pancreatic cancer

• scheduled resection at UHN

• consented to ICGC Pancreatic Cancer Genome Project

• surgery planned for >2 days away (drug administration has to be 16-20hrs before surgery)

Exclusion Criteria:

• not participating in ICGC

• contraindications to pimonidazole (allergy)

• surgery scheduled for same or next day (not enough time to arrange for drug administration)